Impact of HLA matching, type of crossmatch, and immunosuppressive therapy on primary pediatric cadaver renal allograft survival.
Kerman
R H
RH
Department of Surgery, University of Texas Medical School, Houston.
Sullivan
E K
EK
Tejani
A
A
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine